Abstract:
The present invention provides a method for the preparation of compounds of formula (II). The invention also provides novel compounds of formula (II) and their use in medical, scientific and/or biological applications.
Abstract:
Isoflavone compounds are described and recommended as therapeutic agents. Exemplified and preferred compounds are (a). Indications show compounds have good competitive binding to estrogen receptors. This is exemplified
Abstract:
Systems, methods, and machine-readable media are disclosed for providing dynamic and/or conditional constraints on queries based on an external security policy. In one embodiment, a method is provided which comprises receiving from a user a request to access a resource. A condition clause can be read from a grant statement defined in the security policy. The grant statement can define permission for the user to access the requested resource. In some cases, the grant statement can comprise a Java Authentication and Authorization Service (JAAS) grant statement. A query associated with the requested access can be modified based on the permission granted to the user. The modified query can then be made to perform the requested access.
Abstract:
This invention relates to derivatives of substituted azabicyclo hexanes. The compound of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
Abstract:
This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
Abstract:
Novel synthesis methods, to the products of such novel methods, and to uses of these products. In particular, the present invention provides methods for the reactions of furanones, in particular fimbrolides, with amines. The invention has particular application in the synthesis of halogenated 1,5-dihydro-pyrrol-2-one, 5-halomethylene substituted 1,5-dihydropyrrol-2-ones (lactam analogues of fimbriolides), 5-amino substituted furanones and 5-aminomethylene-2(5H)-furanones and their synthetic analogues. The invention also relates to novel compounds and uses thereof.
Abstract:
The invention relates to a cost effective and industrially advantageous process for the selective methylation of a hydroxy group at the 6 position of erythromycin A derivative which comprised methylating the erythromycin A derivative with a methylating agent in a mixture of toluene and a ploar aprotic solvent.
Abstract:
A multistep process for producing 8-chloro-6-(2-fluorophenyl)-1-methyl-4-H-imidazo�1,5a!�1,4! benzodiazepine (midazolam) comprises treating a compound of Formula II with a lower alkyl dithiol to produce a compound of Formula III, wherein n=2 or 3, converting the compound of Formula III to a compound of Formula VII, and then treating the compound of Formula VII with a deprotecting agent, thereby producing midazolam. Novel intermediate compounds are also disclosed.
Abstract:
An agglomeration process in which clay fines alone or in combination with other materials are agglomerated to a usable pellet size for a variety of marketable end products. The clay fines are collected, prepared and blended with conditioners and/or other waste materials in the proportions necessary to produce the desired pellet characteristics. The blended materials are preweighed and measured, permitting batch feeding to the agglomerator. The agglomerated pellets are dried and screened, with the oversize pellets being passed through a granulator to reduce their size and then being rescreened, and the undersized pellets being recycled to the collecting step for reagglomeration. Hence, the process provides pellets of relatively uniform size with little or no waste from the agglomeration procedure. The pellets may be impregnated or coated with a variety of substances, including fertilizers, pesticides, odor reducing substances, and colorants to provide a variety of different end products, including cat box filler, fertilizers, soil conditioners and floor absorbent.